Topline data from a one-month TB006 treatment regimen demonstrate improvements in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score (primary endpoint), suggesting the potential to slow cognitive decline or reverse disease progression. Results for key secondary endpoints were consistent with this primary endpoint, further indicating that TB006 improved cognition in patients.
TB006 treatment was well-tolerated, with only minor adverse events (AEs) reported.
In the Open Label Extension (OLE) study, 119 patients were treated for an average of 8 months. The primary cognitive and functional endpoint, CDR-SB, was well-maintained around baseline levels across the entire patient population.
Once unable to manage daily tasks, a 91-year-old woman now dresses herself, participates in activities, and saw her MMSE score (a tool used to assess mental status) jump from 15 to 25.
Once plagued by nausea, high blood pressure, incontinence, and extreme fatigue, a 90-year-old woman with dementia is now active with family, has stable blood pressure, tolerates cold, and feels better overall. Her MMSE score rose from 18 to 25.
